Compare Coupang Inc (CPNG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Enveric Biosciences Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Coupang Inc is far larger — about 4073.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 27,703,608). Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Enveric Biosciences Inc for 14 Days on average.
| CPNG | ENVB | |
|---|---|---|
Market Cap | $27.70B | $6.80M |
Volume | 27,703,608 | 64,867 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $10.80 |
52-Week Low | $13.75 | $1.27 |
Typical Hold Time | 55 Days | 14 Days |
Enterprise Value | $27.22B | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $15.83, up 6.89% over 24 hours, with a bullish technical signal from moving averages and ADX. The company reported $34.53B revenue in 2025 with a net income of $208M, though recent quarters show earnings misses. Analyst consensus is strongly bullish with a $25.25 price target, and cash flow from operations remains positive at $1.77B.
The outlook is mixed: strong revenue growth and analyst support offer upside, but negative net income margin and high P/E of 184.18 signal overvaluation risks. Key risks include competitive pressure from MercadoLibre and Alibaba, and a projected net loss of $767M in 2026. Institutional sentiment is positive, but earnings volatility requires caution.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
